> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Octapharma locks in $1.5B first US factory after tax-incentive fight
- URL: https://members.americanhealthintel.com/2026-08-01-ledger/
- Published: 2026-08-01T16:12:01.000Z
- Updated: 2026-08-01T16:12:01.000Z
- Description: Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Saturday, August 1, 2026 Octapharma locks in $1.5B first US factory after tax-incentive fight Plus: Bristol Myers Squibb beats Q2 estimates, raises guidance again. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Deal Confidence: High Octapharma, the Swiss maker of plasma-derived critical care medicines, just locked in its first-ever US factory: 1.5 billion dollars in Rock Hill, South Carolina, and about 1,500 jobs. The deal nearly died in a weeks-long fight between York County and Rock Hill over splitting tax incentives before the city council approved it 7-0 on July 24\. Production targets the mid-2030s. Why it matters A major foreign drugmaker is building its first US factory, adding domestic capacity for plasma-derived medicines used in trauma and critical care. Watch whether the mid-2030s timeline holds and how the local tax fight resolves. Sources: [Prnewswire](https://www.prnewswire.com/news-releases/octapharma-to-build-1-5-billion-state-of-the-art-critical-care-manufacturing-facility-in-rock-hill-sc-302838003.html?ref=members.americanhealthintel.com) · [Sc](https://governor.sc.gov/news/2026-07/octapharma-selects-york-county-its-first-us-manufacturing-site?ref=members.americanhealthintel.com) · [Soctv](https://www.wsoctv.com/news/local/after-weeks-debate-rock-hill-approves-octapharma-deal-create-1500-jobs/D35ZAL7ENJBITCFIR6MGR6JCDA/?ref=members.americanhealthintel.com) Earnings Confidence: High Bristol Myers Squibb, the drugmaker behind Opdivo and Eliquis, beat Wall Street's second-quarter revenue estimate by more than a billion dollars and raised its full-year guidance for the second straight quarter. Revenue hit 13 billion dollars, up 6%. The newer Growth Portfolio, including Opdivo Qvantig and Reblozyl, grew 15% and now makes up nearly 60% of total revenue as older drugs lose patent protection. Why it matters One of the largest US drugmakers is outgrowing patent losses on older products, a sign the broader branded-pharma sector's newer drug launches are gaining traction. Watch whether the Growth Portfolio keeps outpacing legacy drug declines. Sources: [SEC](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/bmy-20260730.htm?ref=members.americanhealthintel.com) Also today Lilly and Resilience invest $750M in US GLP-1 manufacturing [Read](https://americanhealthintel.com/editions/2026-08-01-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#lilly-resilience-750-million-ohio-glp1-manufacturing) argenx pays $2.2B, 86% premium, for Forte Biosciences [Read](https://americanhealthintel.com/editions/2026-08-01-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#argenx-forte-biosciences-acquisition) FRONTIER SCAN: Vendor ransomware breach exposes 442,000+ patients [Read](https://americanhealthintel.com/editions/2026-08-01-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#unlimited-systems-ransomware-breach-frontier-scan) 349Records$19.7BEnforcement17Deadlines104Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-01-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |